Drug

Vimseltinib clinical trials

Also written DCC-3014.

studies test it: 9
open now: 3
in phase 3: 1
first study started: 2017

How each study uses vimseltinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the vimseltinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: 14 Feb 2025 · ROMVIMZA · NDA 219304 (FDA, Drugs@FDA)
European Union: 17 Sept 2025 · Romvimza · EMEA/H/C/006363 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Vimseltinib: 7

Development codes

DCC-3014: 5

Studies by the year they started

9 studies that test it; most in 2026 (3)

Studies that test vimseltinib, by start year
Year	Studies
2017	1
2020	1
2021	1
2024	1
2025	2
2026	3

By phase

A phase 1/2 study counts in both.

Phase 1: 6
Phase 2: 3
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Synovitis, Pigmented Villonodular: 2
Sarcoma: 1
Giant Cell Tumor of Tendon Sheath: 1
Bronchiolitis Obliterans Syndrome: 1

Who runs them

Industry 8 · Other 1

Deciphera Pharmaceuticals, LLC (7) · Memorial Sloan Kettering Cancer Center (1) · Ono Pharmaceutical Co., Ltd. (1)

Related medicines

As reviewed, each with the page that says it.

One of Protein Kinase Inhibitors source
One of Tyrosine kinase inhibitors (TKIs) source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test vimseltinib.

Dec 2026Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male ParticipantsPhase 1 · Deciphera Pharmaceuticals, LLC

Studies

Open first, then newest update. How each study uses vimseltinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9

Codes

What other systems call vimseltinib · ClinicalTrials.gg INT002147

MeSH (NLM) C000731840vimseltinibOne source NLM
UNII (FDA) PX9FTM69BFVIMSELTINIBConfirmed FDA, NLM, Wikidata
Wikidata Q106440798vimseltinibConfirmed FDA, NLM, Wikidata
NCI Thesaurus C175876VimseltinibOne source FDA
DrugBank DB17520One source Wikidata

System	Code	Name there	Checked by
MeSH (NLM)	C000731840	vimseltinib	One source NLM
UNII (FDA)	PX9FTM69BF	VIMSELTINIB	Confirmed FDA, NLM, Wikidata
Wikidata	Q106440798	vimseltinib	Confirmed FDA, NLM, Wikidata
NCI Thesaurus	C175876	Vimseltinib	One source FDA
DrugBank	DB17520	—	One source Wikidata

Also registered as vimseltinib dihydrate (UNII 89JWT5T56Y).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.